Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R2W: BCR vs FCR for Waldenstrom's Macroglobulinaemia
NCT01592981Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in Waldenstrom macroglobulinemia (WM) (2 arms), sponsored by University College London. Primary endpoint: Overall Response Rate at 6 months. Started Jan 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01592981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592981.